COMMUNIQUÉS West-GlobeNewswire

Neuronetics and Greenbrook TMS Announce Closing of Transaction
10/12/2024
MALVERN, Pa. and TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”, and together with Neuronetics, the “Combined Company [...]
Soda Health Adds Walgreens to Network of Integrated Retailers, Serving More than 100 Million Medicare Advantage and Medicaid Members
10/12/2024
DEERFIELD, Ill. and BENTONVILLE, Ark., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Soda Health today announced the expansion of the Soda Health Smart Benefits program to include Walgreens, the leading integrated independent [...]
Brain Cancer Canada Awards a $50,000 Grant to Discover How to Use the Body’s Own Immune Cells to Attack Pediatric Brain Cancers
10/12/2024
TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Brain Cancer Canada is excited to announce a $50,000 grant awarded to Dr. Shawn Beug, Scientist at the Children’s Hospital of Eastern Ontario Research Institute, and his team. [...]
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares
10/12/2024
TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public offering (the “ [...]
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
10/12/2024
75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy in updated Phase 1/2 data as of December 9, 2024 Best [...]
India’s First CDSCO Certified Robotic System for Telesurgery: SSi Mantra Leads the Way
10/12/2024
SS Innovations becomes the first and only company in India to receive regulatory approval for Telesurgery and Teleproctoring capabilities of a surgical robotic system, its SSi Mantra, marking a significant achievement [...]
HWH International Inc. and Guangzhou Inbot Technology Ltd Announce Strategic Partnership to Drive Global Robotics Expansion
10/12/2024
BETHESDA, MD, Dec. 10, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. (“HWH”) (Nasdaq: HWH) is proud to announce the signing of a strategic partnership agreement with Guangzhou Inbot Technology Ltd, a robotics company [...]
BioAdaptives, Inc. Launches Xcellara™ Stem Cell Activator – Harnessing Nature for Optimal Health
10/12/2024
LAS VEGAS, Dec. 10, 2024 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives, Inc. (OTC: BDPT) is thrilled to announce the launch of Xcellara™ Stem Cell Activator, a groundbreaking supplement that harnesses the extraordinary [...]
UPDATE – Health-ISAC Bestows Newly Renamed Steve Katz Hero Award
10/12/2024
Rachel James received the cybersecurity threat sharing award ORMOND BEACH, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center ( Health-ISAC ), the non-profit world-class, industry-led [...]
WeightWatchers Unveils Next-Gen Program With AI-Powered App Features
10/12/2024
With access to Registered Dietitians, 150+ New ZeroPoint® Foods and smarter tracking features, the new program delivers a cutting-edge, flexible approach to holistic weight management NEW YORK, Dec. 10, 2024 (GLOBE [...]
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
10/12/2024
– Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Safety [...]
Visory Health Joins Fast Company's Esteemed 2024 Brands That Matter List
10/12/2024
The health tech company is honored to receive an award for its solution to make affordable medications accessible to everyone ESTERO, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Visory Health , a patient-first health tech [...]
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
10/12/2024
Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that the first participant has [...]
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
10/12/2024
Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between anatomical stages 1 Real- [...]
H1 Partners with CTI to Streamline Clinical Trial PI and Site Selection for More Inclusive and Efficient Trials
10/12/2024
Leading Contract Research Organization integrates H1’s Trial Landscape platform to optimize global site selection, enhance diversity efforts, and streamline operational efficiency NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE [...]
ACC Medlink Highlights Commitment to Excellence in Patient Care at ACMA Case Management Conference
10/12/2024
HUNTINGTON BEACH, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ACC Medlink, a leading provider of long-distance medical transportation services, proudly participated in this year’s ACMA Case Management Conference, where [...]
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash
09/12/2024
Basel, 9 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of Poseida Therapeutics, Inc. (Poseida) (NASDAQ: PSTX) [...]
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/12/2024
WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring [...]
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
09/12/2024
Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial 23 months median Overall Survival from date of diagnosis was [...]

Pages